Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T

BACKGROUND: Sipuleucel-T has demonstrated improved overall survival in patients with metastatic castration-resistant prostate cancer (mCRPC). This analysis examined the effect of sipuleucel-T on time to disease-related pain (TDRP) and time to first use of opioid analgesics (TFOA) in mCRPC using data...

Descripción completa

Detalles Bibliográficos
Autores principales: Small, E J, Higano, C S, Kantoff, P W, Whitmore, J B, Frohlich, M W, Petrylak, D P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4160816/
https://www.ncbi.nlm.nih.gov/pubmed/24957547
http://dx.doi.org/10.1038/pcan.2014.21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4160816/
https://www.ncbi.nlm.nih.gov/pubmed/24957547
http://dx.doi.org/10.1038/pcan.2014.21

Ejemplares similares